We therefore measured G protein-dependent cAMP generation and -arrestin-1 and -2 recruitment with exendin-4, exendin-phe1, and exendin-asp3 at two time-points to avoid kinetic artefacts 38 , and calculated the pathway bias by fitting the response data to a modified form of the operational model of agonism 39 (Fig
Its most robust research is in healing the GI tract
Just won't work as well
[DOI] [PubMed] [Google Scholar] 246.Brazeau, P
Risk reduction strategies may include postponement/cancellation of the procedure, ingestion of a clear fluid diet for some period of time before the nothing by mouth period, avoidance of deep sedation/general anesthesia if possible, and use of rapid-sequence induction if general anesthesia is required
SURMOUNT-5 Trial Overview SURMOUNT-5 (NCT05822830) is a multicenter, randomized, open-label Phase 3b trial aimed at assessing the efficacy and safety of Zepbound (tirzepatide) compared to Wegovy (semaglutide) in adults with obesity or overweight, with at least one comorbidity (such as hypertension, dyslipidemia, obstructive sleep apnea (OSA), or cardiovascular disease), and no diabetes